Pharmaron Beijing Co Ltd
HKEX:3759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
HKEX:3759
Watchlist
Price: 21.04 HKD -3.13% Market Closed
Market Cap: HK$60.2B

P/FCFE

31.6
Current
119%
More Expensive
vs 3-y average of 14.4

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
31.6
=
Market Cap
HK$53.5B
/
Free Cash Flow to Equity
¥1.6B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
31.6
=
Market Cap
HK$53.5B
/
Free Cash Flow to Equity
¥1.6B

Valuation Scenarios

Pharmaron Beijing Co Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (14.4), the stock would be worth HK$9.6 (54% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-54%
Maximum Upside
+28%
Average Downside
24%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 31.6 HK$21.04
0%
3-Year Average 14.4 HK$9.6
-54%
5-Year Average 14.7 HK$9.77
-54%
Industry Average 40.6 HK$27
+28%
Country Average 26.4 HK$17.55
-17%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
CN
Pharmaron Beijing Co Ltd
HKEX:3759
52.1B HKD 31.6 31.3
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 2 167.8 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.4B USD 12.2 25.5
US
Danaher Corp
NYSE:DHR
124B USD 19.4 33.6
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 190.3 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
326.9B CNY 21.5 17.1
CH
Lonza Group AG
SIX:LONN
32.9B CHF -40.7 -119.6
US
Agilent Technologies Inc
NYSE:A
32.4B USD 36.5 25.1
US
Waters Corp
NYSE:WAT
30.1B USD 106.9 46.9
US
IQVIA Holdings Inc
NYSE:IQV
26.8B USD 9.8 19.8
US
Mettler-Toledo International Inc
NYSE:MTD
25.8B USD 31.7 29.7

Market Distribution

In line with most companies in China
Percentile
46th
Based on 5 086 companies
46th percentile
22.7
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

Pharmaron Beijing Co Ltd
Glance View

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
28.82 HKD
Undervaluation 27%
Intrinsic Value
Price HK$21.04
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett